iShares系统性替代主动型ETF IALT 深 沪
等待开盘 04-02 09:30:00 美东时间
27.42
+0.154
+0.56%
华盛通- 最 高27.50
- 今 开27.46
- 成交量 22.53万股
- 最 低 27.26
- 昨 收 27.2663
- 总市值 1.32亿
- 52周最高 27.50
- 市盈率 静 --
- 换手率 4.69%
- 52周最低 24.9357
- 委 比 -38.57%
- 总股本 480.00万
- 历史最高 27.50
- 量 比 2.31
- 振 幅 0.88%
- 历史最低 24.9357
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Solenis Announces Energy Surcharge Following Middle East Conflict
BRIEF-Solenis Announces Energy Surcharge Following Middle East Conflict March 18 (Reuters) - SOLENIS ANNOUNCES ENERGY SURCHARGE FOLLOWING MIDDLE EAST CONFLICT SOLENIS: WILL IMPLEMENT A GLOBAL ENERGY SURCHARGE OF 8-14%, EFFECTIVE APRIL 1 SOLENIS: CO'S SUPPLY CHAIN TEAMS ACTIVELY MANAGING GLOBAL FLOWS
03-18 21:17
BRIEF-Glenmark Specialty SA Receives U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol Usp, 44 Mcg Per Actuation, With 180-Day Competitive Generic Therapy Exclusivity
BRIEF-Glenmark Specialty SA Receives U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol Usp, 44 Mcg Per Actuation, With 180-Day Competitive Generic Therapy Exclusivity March 4 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS : GLENMARK SPECIALTY SA RECEIVES U.S. FDA APPROVAL FOR FLUTICA
03-04 20:02
Perimeter Solutions Q4 net sales rise 19%
Perimeter Solutions Q4 net sales rise 19% Overview Industrial products provider's Q4 net sales rose 19% yr/yr Company reported Q4 net loss of $140.2 mln vs year-ago profit Specialty Products segment acquired new product lines in Q4 2025 Outlook Perimeter Solutions did not give any specific financial
02-26 19:10
BRIEF-Merck Evolves Human Health Operating Structure To Support Portfolio Execution
BRIEF-Merck Evolves Human Health Operating Structure To Support Portfolio Execution Feb 23 (Reuters) - Merck & Co Inc MRK.N : MERCK EVOLVES HUMAN HEALTH OPERATING STRUCTURE TO SUPPORT PORTFOLIO EXECUTION MERCK & CO INC - ORGANIZES HUMAN HEALTH INTO TWO BUSINESS UNITS MERCK & CO INC: ORGANIZING ITS H
02-23 20:15
Balchem Q4 revenue beats on Human Nutrition and Health unit strength
Balchem Q4 revenue beats on Human Nutrition and Health unit strength Overview Nutritional ingredients maker's Q4 revenue rose 9.8%, beating analyst expectations Adjusted EBITDA for Q4 grew 8.1% yr/yr, driven by segment sales growth Company repurchased $53.6 mln of common stock during Q4 Outlook Balc
02-20 20:20
BRIEF-Ategrity Specialty Insurance Says On Feb 12, Board Authorized $50 Mln Share Repurchase Program
BRIEF-Ategrity Specialty Insurance Says On Feb 12, Board Authorized $50 Mln Share Repurchase Program Feb 19 (Reuters) - Ategrity Specialty Insurance Company Holdings ASIC.N : ATEGRITY SPECIALTY INSURANCE CO HOLDINGS - ON FEB 12,BOARD AUTHORIZES $50 MILLION SHARE REPURCHASE PROGRAM - SEC FILING Sourc
02-20 05:48
LKQ Q4 revenue rises 2.7%, beats expectations
LKQ Q4 revenue rises 2.7%, beats expectations Overview Auto parts provider's Q4 revenue rose 2.7%, beating analyst expectations Adjusted EPS for Q4 missed analyst expectations Company initiated strategic review to enhance shareholder value Outlook LKQ anticipates 2026 organic revenue growth for part
02-19 20:10
BRIEF-Sanofi Appoints Manuela Buxo As Head Of Specialty Care
BRIEF-Sanofi Appoints Manuela Buxo As Head Of Specialty Care Feb 17 (Reuters) - Sanofi SA SASY.PA : ANNOUNCES LEADERSHIP EVOLUTION IN SPECIALTY CARE BUSINESS UNIT APPOINTMENT OF MANUELA BUXO AS HEAD OF SPECIALTY CARE, EFFECTIVE MARCH 1, 2026 BRIAN FOARD HAS DECIDED TO LEAVE COMPANY AS OF FEBRUARY 28
02-17 21:34
BRIEF-Fitch Expects European Insurance M&A To Accelerate In 2026
BRIEF-Fitch Expects European Insurance M&A To Accelerate In 2026 Feb 16 (Reuters) - Fitch: FITCH: EUROPEAN INSURANCE M&A TO ACCELERATE IN 2026 FITCH: EXPECT INCREASED M&A ACTIVITY IN SPECIALTY AND REINSURANCE, UK, DUTCH AND GERMAN LIFE, AND EUROPEAN BANCASSURANCE
02-16 23:05
Avient Q4 sales beat on Specialty Engineered Materials unit strength
Avient Q4 sales beat on Specialty Engineered Materials unit strength Overview Materials solutions innovator's Q4 sales rose 2%, beating analyst expectations Adjusted EPS for Q4 grew 14% yr/yr, driven by organic sales growth 2026 adjusted EPS forecasted to grow 4% to 12% Outlook Avient expects 2026 a
02-12 19:25
